Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
MLLNF Quote, Financials, Valuation and Earnings
Last price:
$6.40
Seasonality move
:
9.85%
Day range:
$6.40 - $6.40
52-week range:
$6.40 - $6.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.12x
P/B ratio:
0.60x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$120.9M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MLLNF
Malin Corp. Plc
|
-- | -- | -- | -- | -- |
|
GHRS
GH Research Plc
|
-- | -$0.23 | -- | -62.11% | $30.38 |
|
ITRM
Iterum Therapeutics Plc
|
-- | -$0.24 | -- | -49.47% | $5.50 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.17% | 106.38% | $213.00 |
|
MURA
Mural Oncology Plc
|
-- | -$0.59 | -- | -81.57% | $5.00 |
|
PRTA
Prothena Corp. Plc
|
$6.6M | -$0.54 | -68.6% | -57.29% | $20.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MLLNF
Malin Corp. Plc
|
$6.40 | -- | $120.9M | -- | $0.00 | 0% | 3.12x |
|
GHRS
GH Research Plc
|
$12.79 | $30.38 | $793M | -- | $0.00 | 0% | -- |
|
ITRM
Iterum Therapeutics Plc
|
$0.31 | $5.50 | $14M | -- | $0.00 | 0% | 29.49x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$170.80 | $213.00 | $10.4B | 15.09x | $0.00 | 0% | 2.51x |
|
MURA
Mural Oncology Plc
|
$2.04 | $5.00 | $35.4M | -- | $0.00 | 0% | -- |
|
PRTA
Prothena Corp. Plc
|
$9.69 | $20.33 | $521.6M | -- | $0.00 | 0% | 44.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MLLNF
Malin Corp. Plc
|
-- | 0.000 | -- | -- |
|
GHRS
GH Research Plc
|
0.2% | 2.392 | 0.07% | 27.72x |
|
ITRM
Iterum Therapeutics Plc
|
128.01% | 0.805 | 112.75% | 1.78x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
|
MURA
Mural Oncology Plc
|
6.04% | 2.518 | 9.89% | 5.75x |
|
PRTA
Prothena Corp. Plc
|
2.99% | 1.493 | 1.73% | 6.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MLLNF
Malin Corp. Plc
|
-- | -- | -- | -- | -- | -- |
|
GHRS
GH Research Plc
|
-$89K | -$16.5M | -16.82% | -16.86% | -- | -$14.5M |
|
ITRM
Iterum Therapeutics Plc
|
$15K | -$7.7M | -98.23% | -- | -1982.31% | -$7.9M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
MURA
Mural Oncology Plc
|
-$800K | -$4M | -104.55% | -111% | -- | -$18.5M |
|
PRTA
Prothena Corp. Plc
|
$1.5M | -$39.8M | -65.85% | -67.47% | -1646.42% | -$43.2M |
Malin Corp. Plc vs. Competitors
-
Which has Higher Returns MLLNF or GHRS?
GH Research Plc has a net margin of -- compared to Malin Corp. Plc's net margin of --. Malin Corp. Plc's return on equity of -- beat GH Research Plc's return on equity of -16.86%.
Company Gross Margin Earnings Per Share Invested Capital MLLNFMalin Corp. Plc-- -- -- GHRSGH Research Plc-- -$0.23 $292M -
What do Analysts Say About MLLNF or GHRS?
Malin Corp. Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand GH Research Plc has an analysts' consensus of $30.38 which suggests that it could grow by 137.58%. Given that GH Research Plc has higher upside potential than Malin Corp. Plc, analysts believe GH Research Plc is more attractive than Malin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings MLLNFMalin Corp. Plc0 0 0 GHRSGH Research Plc5 0 0 -
Is MLLNF or GHRS More Risky?
Malin Corp. Plc has a beta of -0.134, which suggesting that the stock is 113.447% less volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MLLNF or GHRS?
Malin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Malin Corp. Plc pays -- of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MLLNF or GHRS?
Malin Corp. Plc quarterly revenues are --, which are smaller than GH Research Plc quarterly revenues of --. Malin Corp. Plc's net income of -- is lower than GH Research Plc's net income of -$14M. Notably, Malin Corp. Plc's price-to-earnings ratio is -- while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Malin Corp. Plc is 3.12x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MLLNFMalin Corp. Plc3.12x -- -- -- GHRSGH Research Plc-- -- -- -$14M
-
Which has Higher Returns MLLNF or ITRM?
Iterum Therapeutics Plc has a net margin of -- compared to Malin Corp. Plc's net margin of -2302.31%. Malin Corp. Plc's return on equity of -- beat Iterum Therapeutics Plc's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MLLNFMalin Corp. Plc-- -- -- ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M -
What do Analysts Say About MLLNF or ITRM?
Malin Corp. Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 1651.04%. Given that Iterum Therapeutics Plc has higher upside potential than Malin Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Malin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings MLLNFMalin Corp. Plc0 0 0 ITRMIterum Therapeutics Plc1 0 0 -
Is MLLNF or ITRM More Risky?
Malin Corp. Plc has a beta of -0.134, which suggesting that the stock is 113.447% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191.032%.
-
Which is a Better Dividend Stock MLLNF or ITRM?
Malin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Malin Corp. Plc pays -- of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MLLNF or ITRM?
Malin Corp. Plc quarterly revenues are --, which are smaller than Iterum Therapeutics Plc quarterly revenues of $390K. Malin Corp. Plc's net income of -- is lower than Iterum Therapeutics Plc's net income of -$9M. Notably, Malin Corp. Plc's price-to-earnings ratio is -- while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Malin Corp. Plc is 3.12x versus 29.49x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MLLNFMalin Corp. Plc3.12x -- -- -- ITRMIterum Therapeutics Plc29.49x -- $390K -$9M
-
Which has Higher Returns MLLNF or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -- compared to Malin Corp. Plc's net margin of 22.33%. Malin Corp. Plc's return on equity of -- beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital MLLNFMalin Corp. Plc-- -- -- JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About MLLNF or JAZZ?
Malin Corp. Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 24.71%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Malin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Malin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings MLLNFMalin Corp. Plc0 0 0 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is MLLNF or JAZZ More Risky?
Malin Corp. Plc has a beta of -0.134, which suggesting that the stock is 113.447% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.
-
Which is a Better Dividend Stock MLLNF or JAZZ?
Malin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Malin Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MLLNF or JAZZ?
Malin Corp. Plc quarterly revenues are --, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Malin Corp. Plc's net income of -- is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Malin Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Malin Corp. Plc is 3.12x versus 2.51x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MLLNFMalin Corp. Plc3.12x -- -- -- JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M
-
Which has Higher Returns MLLNF or MURA?
Mural Oncology Plc has a net margin of -- compared to Malin Corp. Plc's net margin of --. Malin Corp. Plc's return on equity of -- beat Mural Oncology Plc's return on equity of -111%.
Company Gross Margin Earnings Per Share Invested Capital MLLNFMalin Corp. Plc-- -- -- MURAMural Oncology Plc-- -$0.21 $58.7M -
What do Analysts Say About MLLNF or MURA?
Malin Corp. Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Mural Oncology Plc has an analysts' consensus of $5.00 which suggests that it could grow by 194.12%. Given that Mural Oncology Plc has higher upside potential than Malin Corp. Plc, analysts believe Mural Oncology Plc is more attractive than Malin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings MLLNFMalin Corp. Plc0 0 0 MURAMural Oncology Plc0 1 0 -
Is MLLNF or MURA More Risky?
Malin Corp. Plc has a beta of -0.134, which suggesting that the stock is 113.447% less volatile than S&P 500. In comparison Mural Oncology Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MLLNF or MURA?
Malin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mural Oncology Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Malin Corp. Plc pays -- of its earnings as a dividend. Mural Oncology Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MLLNF or MURA?
Malin Corp. Plc quarterly revenues are --, which are smaller than Mural Oncology Plc quarterly revenues of --. Malin Corp. Plc's net income of -- is lower than Mural Oncology Plc's net income of -$3.7M. Notably, Malin Corp. Plc's price-to-earnings ratio is -- while Mural Oncology Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Malin Corp. Plc is 3.12x versus -- for Mural Oncology Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MLLNFMalin Corp. Plc3.12x -- -- -- MURAMural Oncology Plc-- -- -- -$3.7M
-
Which has Higher Returns MLLNF or PRTA?
Prothena Corp. Plc has a net margin of -- compared to Malin Corp. Plc's net margin of -1513.09%. Malin Corp. Plc's return on equity of -- beat Prothena Corp. Plc's return on equity of -67.47%.
Company Gross Margin Earnings Per Share Invested Capital MLLNFMalin Corp. Plc-- -- -- PRTAProthena Corp. Plc60.95% -$0.68 $304.1M -
What do Analysts Say About MLLNF or PRTA?
Malin Corp. Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.33 which suggests that it could grow by 109.84%. Given that Prothena Corp. Plc has higher upside potential than Malin Corp. Plc, analysts believe Prothena Corp. Plc is more attractive than Malin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings MLLNFMalin Corp. Plc0 0 0 PRTAProthena Corp. Plc2 2 0 -
Is MLLNF or PRTA More Risky?
Malin Corp. Plc has a beta of -0.134, which suggesting that the stock is 113.447% less volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.099, suggesting its less volatile than the S&P 500 by 109.869%.
-
Which is a Better Dividend Stock MLLNF or PRTA?
Malin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Malin Corp. Plc pays -- of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MLLNF or PRTA?
Malin Corp. Plc quarterly revenues are --, which are smaller than Prothena Corp. Plc quarterly revenues of $2.4M. Malin Corp. Plc's net income of -- is lower than Prothena Corp. Plc's net income of -$36.5M. Notably, Malin Corp. Plc's price-to-earnings ratio is -- while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Malin Corp. Plc is 3.12x versus 44.25x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MLLNFMalin Corp. Plc3.12x -- -- -- PRTAProthena Corp. Plc44.25x -- $2.4M -$36.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
